Reliability and Validity of the Korean Version of the Spinal and Bulbar Muscular Atrophy Functional Rating Scale
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) is a reliable and valid instrument for evaluating the functional status of patients with spinal and bulbar muscular atrophy (SBMA). This study aimed to validate a Korean version of the SBMAFRS in an SBMA population. Methods We applied the SBMAFRS to 64 SBMA patients at their regular follow-up clinical visits. The patients underwent clinical evaluations that included the 6-minute walking test (6MWT), forced vital capacity (FVC), manual muscle test, and the Penetration-Aspiration Scale (PAS). To estimate the stability of the SBMAFRS, the scale was reapplied to a subset of 31 randomly selected patients within 4 weeks of the initial test. The convergent validity was evaluated, and correlations were examined between SBMAFRS items and the muscular force, the total and subscores on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), FVC, PAS score, age at onset, disease duration, and 6MWT results. Results The internal consistency of the scale was confirmed by a high Cronbach’s alpha (total raw alpha=0.867, total standardized alpha=0.863). The test-retest reliability as assessed by Spearman’s rho was also high. The total score and subscores of the SBMAFRS were strongly correlated with the respective items and subscores of the ALSFRS-R, respiratory function, and the 6MWT. Conclusions We have performed a validation study of the Korean version of a disease-specific functional rating scale for SBMA patients. The SBMAFRS is a useful tool for clinical practice and as a potential outcome measure for Korean SBMA patients.
Abstract
Background and Purpose The Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) is a reliable and valid instrument for evaluating the functional status of patients with spinal and bulbar muscular atrophy (SBMA). This study aimed to validate a Korean version of the SBMAFRS in an SBMA population. Methods We applied the SBMAFRS to 64 SBMA patients at their regular follow-up clinical visits. The patients underwent clinical evaluations that included the 6-minute walking test (6MWT), forced vital capacity (FVC), manual muscle test, and the Penetration-Aspiration Scale (PAS). To estimate the stability of the SBMAFRS, the scale was reapplied to a subset of 31 randomly selected patients within 4 weeks of the initial test. The convergent validity was evaluated, and correlations were examined between SBMAFRS items and the muscular force, the total and subscores on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), FVC, PAS score, age at onset, disease duration, and 6MWT results. Results The internal consistency of the scale was confirmed by a high Cronbach’s alpha (total raw alpha=0.867, total standardized alpha=0.863). The test-retest reliability as assessed by Spearman’s rho was also high. The total score and subscores of the SBMAFRS were strongly correlated with the respective items and subscores of the ALSFRS-R, respiratory function, and the 6MWT. Conclusions We have performed a validation study of the Korean version of a disease-specific functional rating scale for SBMA patients. The SBMAFRS is a useful tool for clinical practice and as a potential outcome measure for Korean SBMA patients.
참고문헌 (14)
- Lee JH, "Phenotypic variability in Kennedy’s disease : implication of the early diagnostic features", Acta Neurol Scand, 112, pp.57~63 (2005)
- Rhodes LE, "Clinical features of spinal and bulbar muscular atrophy", Brain, 132, pp.3242~3251 (2009)
- Querin G, "Kennedy disease (X-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy", Rev Neurol (Paris), 173, pp.326~337 (2017)
- Manzano R, "Beyond motor neurons : expanding the clinical spectrum in Kennedy’s disease", J Neurol Neurosurg Psychiatry, 89, pp.808~812 (2018)
- Atsuta N, "Natural history of spinal and bulbar muscular atrophy(SBMA) : a study of 223 Japanese patients", Brain, 129, pp.1446~1455 (2006)
- Hashizume A, "Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy", Brain, 135, pp.2838~2848 (2012)
- Hashizume A, "A functional scale for spinal and bulbar muscular atrophy : cross-sectional and longitudinal study", Neuromuscul Disord, 25, pp.554~562 (2015)
- Querin G, "Validation of the Italian version of the SBMA Functional Rating Scale as outcome measure", Neurol Sci, 37, pp.1815~1821 (2016)
- Kimura F, "Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS", Neurology, 66, pp.265~267 (2006)
- Katsuno M, "Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 9, pp.875~884 (2010)
- de Carvalho M, "Diaphragmatic neurophysiology and respiratory markers in ALS", Front Neurol, 10, pp.143~ (2019)
- Trang H, "Massive CAG repeat expansion and somatic instability in maternally transmitted infantile spinocerebellar ataxia type 7", JAMA Neurol, 72, pp.219~223 (2015)
- Swami M, "Somatic expansion of the Huntington’s disease CAG repeat in the brain is associated with an earlier age of disease onset", Hum Mol Genet, 18, pp.3039~3047 (2009)
- Park D, "Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 correlates with the sixminute walk test and CTG repeats", Neuromuscul Disord, 28, pp.29~37 (2018)